There are lots of great articles on LLM. Based on Deedee's request at our meeting today, I am sharing two that might be of interest.
I am also sharing the publication I referred to regarding amyloid peptide controversies. Either of these topics would be interesting to explore further - possibly seeing if we could get someone that can speak to preclinical models of Alzheimer's disease (and whether they can identify the two-edged sword associated with potential preventative therapies) or explore opportunities to get more insights into the strengths, weaknesses, and potential refinements and applications of LLMs.
------------------------------
Marilyn Martinez Ph.D., FAAPS
Senior Biomedical Research Scientist
US Food and Drug Administration
College Park MD
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------